

## THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. What was the hazard ratio for overall survival (OS) reported in the long-term follow-up of the Phase III EV-302 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy for previously untreated locally advanced or metastatic urothelial carcinoma?
  - a. 0.25
  - b. 0.51
  - c. 0.76
  - d. 0.98
2. The Phase III NIAGARA study of neoadjuvant durvalumab in combination with chemotherapy followed by radical cystectomy and adjuvant durvalumab for muscle-invasive bladder cancer reported what major efficacy outcomes with perioperative durvalumab in combination with chemotherapy versus chemotherapy alone?
  - a. No significant improvement in event-free survival (EFS) or OS
  - b. A significant improvement in EFS only
  - c. A significant improvement in both EFS and OS
  - d. EFS and OS data were immature at the time of presentation
3. The Phase III TiNivo-2 study of tivozanib with nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma (RCC) following 1 or 2 prior therapies including an immune checkpoint inhibitor reported what major efficacy outcomes with tivozanib in combination with nivolumab?
  - a. No significant improvement in progression-free survival (PFS) or OS
  - b. A significant improvement in PFS only
  - c. A significant improvement in both PFS and OS
4. The final analysis from the Phase III CheckMate 9ER study of nivolumab in combination with cabozantinib versus sunitinib for previously untreated advanced RCC reported what major efficacy finding with nivolumab in combination with cabozantinib?
  - a. No significant improvement in PFS or OS
  - b. A significant improvement in PFS only
  - c. A significant improvement in both PFS and OS
5. In the Phase III PEACE-3 study of radium-223 with enzalutamide versus enzalutamide monotherapy in asymptomatic or mildly symptomatic patients with castration-resistant prostate cancer metastatic to the bone, what was the hazard ratio for OS with the radium-223 with enzalutamide combination?
  - a. 0.23
  - b. 0.41
  - c. 0.69
  - d. 0.98